Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Most Americans Lose Sleep Due to 'Digital Distractions.' Experts Offer Tips to Help
SATURDAY, Dec. 9, 2023 -- It has likely happened to everyone at some point: You are poised to go to sleep, but instead a "digital distraction" keeps you up...
CDC: Number of Cantaloupe-Related Salmonella Cases Has Doubled
FRIDAY, Dec. 8, 2023 -- U.S. health officials reported Thursday that the number of cases of cantaloupe-related Salmonella has doubled. "Since the last update...
First Gene-Editing Therapies for Sickle Cell Disease Approved by FDA
FRIDAY, Dec. 8, 2023 -- Two milestone gene therapies for sickle cell disease have been approved by the U.S. Food and Drug Administration. Casgevy is the first...
Geographic Variability Seen in County-Level Preterm Birth Rates
FRIDAY, Dec. 8, 2023 -- Considerable geographic variability is seen in county-level preterm birth rates, according to a study published online Dec. 8 in JAMA...
SABCS: Outcomes No Worse for Survivors With Less Frequent Mammograms
FRIDAY, Dec. 8, 2023 -- For women with breast cancer aged 50 years or older and three years postdiagnosis, outcomes are no worse with less frequent mammograms...
Adenotonsillectomy No Aid for Neurodevelopmental Outcomes in Children
FRIDAY, Dec. 8, 2023 -- In children with mild sleep-disordered breathing (SDB), adenotonsillectomy does not significantly improve executive function or...
FDA Approves Landmark Sickle Cell Gene Therapies, Casgevy and Lyfgenia
FRIDAY, Dec. 8, 2023 -- The U.S. Food and Drug Administration on Friday approved two milestone gene therapies for sickle cell disease, including the first...
Women With Very Early Breast Cancer May Safely Skip Radiation Rx: Study
FRIDAY, Dec. 8, 2023 -- Some women with a very early form of breast cancer known as ductal carcinoma in situ (DCIS) can safely skip follow-up radiation therapy...
Hospitals in Ukraine Seeing Surge in Drug-Resistant Infections: CDC
FRIDAY, Dec. 8, 2023 -- As the war in the Ukraine rages on, new research shows that hospitals there are waging a battle of their own against a different kind...
Can Breast Cancer Survivors Reduce Frequency of Mammograms?
FRIDAY, Dec. 8, 2023 -- Under current U.S. guidelines, women over 49 who've survived early-stage breast cancer are directed to undergo a mammogram every year...
FDA Approves Fabhalta (iptacopan) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Basel, December 6, 2023 — Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral...
FDA Approves Ogsiveo (nirogacestat) for Adults with Desmoid Tumors
STAMFORD, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on...
FDA Approves Ryzneuta (efbemalenograstim alfa) for Chemotherapy-Induced Neutropenia
November 22, 2023, New Jersey – Evive Biotech (Evive), a global biopharmaceutical company devoted to developing novel biologic therapies and a subsidiary...
FDA Approves Truqap (capivasertib) plus Faslodex for Patients with Advanced HR-Positive Breast Cancer
17 November 2023 -- AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult...
Merck Provides Update on FDA Advisory Committee Meeting Evaluating Gefapixant
RAHWAY, N.J., Nov. 17, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the outcome of the U.S. Food and...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients...
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD) ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) --...
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) --X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune...
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a...
New Hybrid Treatment Forces Cancer Cells to Starve
NEW YORK, Dec. 9, 2023. The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows. The work...
Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia
COPENHAGEN, Denmark, Dec. 7, 2023. Vesper Bio ApS ("Vesper" or "the Company"), a clinical stage biotech and world leader in sortilin receptor biology, today...
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
SAN JOSE, Calif., Dec. 6, 20203. Anixa Biosciences ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer...
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
WALTHAM, Mass., Dec. 5, 2023. Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced it...
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
NEW HAVEN, Conn., Dec. 5, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.